Abstract 17P
Background
Breast Cancer is the most common yet preventable & treatable forms of cancer in the Philippines, hence a need to prioritize & strengthen organized screening programs to detect early & bridge to treatment to increase survival. The ACT Now PRIME CARE for Breast Cancer aims to detect breast cancer thru screening using integrated patient online education & self-evaluation with mobile clinic clinical breast exam, ultrasound, navigation to referral pathways for Centers with Medical Access Programs.
Methods
Women ages 40-60, were advised to register at actnow.philcancer.org.ph to access videos on breast health, cancer & self-exam. Patients' self-reported signs, symptoms & risk factors were triaged into high risk & low risk. Immediate scheduling of high-risk individuals to mobile clinic visit were done while low-risk individuals were advised to visit on a yearly basis. Patient education, Clinical Breast Exam & Ultrasound were performed. Both high risk & low risk groups were scheduled for teleconsultation or clinic visits. Suspicious breast findings were referred for immediate biopsy. Confirmed malignancy were referred to centers with medical access programs.
Results
Among women who completed the educational videos, 87% were evaluated to have good comprehension of the materials. Among 1,790 women screened, 277 were clinically high-risk patients & only 6 had breast ultrasound BIRADS 4-5. Two had negative biopsy results. Four had pending biopsy results. Two had confirmed positive early breast malignancy who were subsequently referred treatment. Turnaround time from work-up to treatment was 4 weeks. Among 1513 low risk women, majority have commitments to visit for screening once a year.
Conclusions
In a limited resource country, there's a need to strengthen community-based cancer screening, strengthen patient navigation & improve patients' awareness on available financial & medical access programs to improve compliance & survival. The ACT Now PRIME CARE is a pilot program to enhance education about breast health & cancer, capture cases in the community & provide immediate referral pathways to improve outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Philippine Cancer Society.
Funding
Philippine Cancer Society.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
581P - The associations between afatinib-related adverse events and survival outcomes in patients with lung cancer
Presenter: Wen-Chen Tang
Session: Poster Display
Resources:
Abstract
582P - Furmonertinib treatment in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study
Presenter: Haiyang Chen
Session: Poster Display
Resources:
Abstract
583P - RHBDL2 promotes non-small cell lung cancer metastasis and osimertinib resistance by activating the RAS/MEK/ERK signaling pathway through interaction with FGFR
Presenter: jun Deng
Session: Poster Display
Resources:
Abstract
584P - Upfront aumolertinib for preventing symptomatic central nervous system(CNS) metastases in EGFR-mutant non-small cell lung cancer without baseline CNS metastasis
Presenter: Tangfeng Lv
Session: Poster Display
Resources:
Abstract
585P - Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib
Presenter: Tony S.K. Mok
Session: Poster Display
Resources:
Abstract
586P - Clinical validation of a multiplex polymerase chain reaction (mPCR) assay to identify patients (pts) with NSCLC suitable for mobocertinib treatment
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
587P - Exploring the prevalence and characteristics of human epidermal growth factor receptor 2 (HER2) alterations in non-small cell lung cancer: Analysis from a Malaysian cohort
Presenter: Ning Yi Yap
Session: Poster Display
Resources:
Abstract
588P - First real-world study with HER2 ADC in treating HER2-altered non-small cell lung cancer
Presenter: Kaihua Lu
Session: Poster Display
Resources:
Abstract
590P - A retrospective study of the prevalence and clinical outcomes of KRAS G12C mutated advanced non-small cell lung cancer (NSCLC) in Australian patients (pts)
Presenter: Ben Markman
Session: Poster Display
Resources:
Abstract
591P - The utility of next generation sequencing for KRAS gene variants prevalence in cytological and tissue samples in real-world NSCLC patients: A large single institution real-world study
Presenter: Adam Pluzanski
Session: Poster Display
Resources:
Abstract